Propeller Health, provider of an FDA-cleared digital health solution for improving outcomes in asthma and chronic obstructive pulmonary disease (COPD), today announced a development agreement and R&D collaboration with GSK for its Ellipta® inhaler, the pharmaceutical company’s innovative, patented, dry powder inhaler. Read the full story here.
WisBusiness: Propeller Health announces development agreement and research collaboration with GSK
by Allen | Dec 2, 2015 | Featured, NEWSROOM, Tech Council News